Saol Therapeutics: Saol doses first subject in Phase II limb spasticity treatment trial
The trial will evaluate the safety, pharmacokinetics and efficacy of SL-1002 in adults with limb spasticity. The post Saol doses first subject in Phase II limb spasticity treatment trial appeared first on Clinical Trials Arena.
Read full article »
Saol Therapeutics is a Georgia-based pharmaceutical company that provides therapies for CNS disorders such as pain management, spasticity, and orphan diseases.
Read more